The TRIM2 Knockout A549 Cell Line is a CRISPR/Cas9-edited human lung adenocarcinoma cell line engineered for loss-of-function studies of the TRIM2 gene. This product provides a stable knockout model in the A549 host cell background, generated through CRISPR/Cas9-mediated gene disruption of the endogenous TRIM2 locus. The resulting cell line enables researchers to investigate the functional consequences of TRIM2 ablation in a lung epithelial context, without the need for transient silencing approaches. It is supplied as an adherent cell line ready for expansion and downstream analysis, offering a consistent and renewable resource for experiments focused on ubiquitin-proteasome system regulation and apoptosis signaling.
The host cell line A549 is a widely used model for human lung adenocarcinoma, originally derived from a 58-year-old male with alveolar basal epithelial cell characteristics. These cells harbor a homozygous KRAS G12S mutation, a common oncogenic driver in non-small cell lung cancer, and exhibit adherent epithelial morphology. A549 cells are frequently employed in cancer biology to study signaling pathways, drug responses, and metabolic adaptations, making them an appropriate platform for examining the interplay between E3 ubiquitin ligase activity and oncogenic processes. Their established use in xenograft and in vitro proliferation assays further supports translational research in lung adenocarcinoma.
TRIM2 encodes a member of the tripartite motif (TRIM) family of E3 ubiquitin ligases, which functions in the ubiquitin-proteasome system by catalyzing the transfer of ubiquitin from E2 ubiquitin-conjugating enzymes to specific substrates, targeting them for 26S proteasomal degradation. Key downstream targets include neurofilament light chain (NEFL), a neuronal intermediate filament protein, and the pro-apoptotic BCL2 family member BCL2L11 (Bim). TRIM2 directly interacts with NEFL and Bim, and its ligase activity promotes their ubiquitination and subsequent degradation. Additionally, TRIM2 has been reported to interact with MYO5A, a myosin motor protein, though the functional significance in A549 cells remains to be fully elucidated. By controlling the levels of these substrates, TRIM2 influences neurofilament dynamics and apoptotic signaling, with potential crosstalk to caspase activation pathways involving BAX.
In the A549 cellular environment, TRIM2 knockout disrupts the normal degradation of Bim, a critical sentinel of the intrinsic apoptosis pathway, potentially sensitizing cells to apoptotic stimuli or altering basal cell survival. Concomitantly, stabilization of NEFL may introduce ectopic neurofilament-related stress responses, though the relevance in a non-neuronal lineage requires careful contextual interpretation. This knockout cell line thus serves as a valuable tool for dissecting how an E3 ligase contributes to the fine-tuning of apoptosis and proliferation in lung adenocarcinoma. It also offers a unique isogenic background to examine potential non-neuronal functions of neurofilament components and their impact on cancer cell homeostasis.
Researchers can employ the TRIM2 Knockout A549 Cell Line in a variety of experimental settings. Typical applications include investigating the role of ubiquitin-mediated degradation in apoptosis regulation using Annexin V assays or caspase activation readouts, assessing changes in cell proliferation via MTT or clonogenic assays, and performing ubiquitination assays to validate substrate stabilization. The model is also suitable for drug screening campaigns targeting the ubiquitin-proteasome system or TRIM2-interacting pathways, as well as for mechanistic studies using co-immunoprecipitation to map protein interactions and RNA-seq to define transcriptional consequences of TRIM2 loss. Moreover, it can be utilized to model aspects of Charcot-Marie-Tooth disease type 2R in a manipulable in vitro system. For detailed product specifications, validation data, or support, please contact Ascent Research.
